Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Maxcyte (MXCT) Equity Average (2020 - 2026)

Maxcyte has reported Equity Average over the past 6 years, most recently at $175.9 million for Q4 2025.

  • Quarterly Equity Average fell 16.16% to $175.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $175.9 million through Dec 2025, down 16.16% year-over-year, with the annual reading at $188.9 million for FY2025, 13.84% down from the prior year.
  • Equity Average was $175.9 million for Q4 2025 at Maxcyte, down from $185.5 million in the prior quarter.
  • Over five years, Equity Average peaked at $263.5 million in Q4 2021 and troughed at $57.3 million in Q1 2021.
  • The 5-year median for Equity Average is $226.5 million (2024), against an average of $210.5 million.
  • Year-over-year, Equity Average skyrocketed 672.52% in 2021 and then dropped 16.16% in 2025.
  • A 5-year view of Equity Average shows it stood at $263.5 million in 2021, then dropped by 3.53% to $254.2 million in 2022, then fell by 8.43% to $232.8 million in 2023, then dropped by 9.88% to $209.8 million in 2024, then dropped by 16.16% to $175.9 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Equity Average are $175.9 million (Q4 2025), $185.5 million (Q3 2025), and $195.1 million (Q2 2025).